ADGRG2

Across TCGA pan-cancer cohorts, ADGRG2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ADGRG2 data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ADGRG2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADGRG2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

COAD, ESCA, and SCLC are the cancer types where ADGRG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.302	0.797	<.001	22	view →
ESCA	DFS	Median	All	0.023	0.533	<.001	18	view →
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →
UCEC	OS	Median	IV	0.259	0.770	<.001	12	view →
BLCA	DFS	Median	III,IV	0.816	0.290	.024	9	view →
CHOL	DFS	Median	All	0.037	0.486	.001	6	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ADGRG2–COAD (DFS)

Open the COAD breakdown →